2016

Cynvenio Clinical Trial Data Supports Benefits of Multi-Template Liquid Biopsy Sequencing for Cancer Mutational Profiling

April 5, 2016 — Molecular diagnostic approaches to cancer detection and monitoring can benefit from a multiple-template strategy that analyzes DNA from circulating tumor cells (ctcDNA) and circulating cell free DNA (ccfDNA) in blood, as well as from tissue biopsies, according to new NCI-supported clinical trial published by scientists from Cynvenio Biosystems, Inc., and collaborators. The new research was published online in the journal Oncotarget.

Genome Web: Mt. Sinai Studying CTCs, ctDNA in Context of Triple Negative Breast Cancer

April 1, 2016 - Genome web article highlighting a trial by researchers at Mount Sinai to evaluate the genomic profiles of ctDNA and CTCs as well as phenotypic features of CTCs in patients with triple negative breast cancer to study the relationships between the two and how they correlate with disease. The group will use Cynvenio's LiquidBiopsy microfluidic system to isolate CTCs, ctDNA, and germline DNA.

Cynvenio Honors Triple Negative Breast Cancer Day with Clinical Trial Launch and Event at Pink Lotus Breast Center in Los Angeles

March 3, 2016 – Cynvenio Biosystems, Inc. honors Triple Negative Breast Cancer Day by launching a clinical trial for women with triple negative breast cancer (TNBC) using the company’s non-invasive liquid biopsy technology to monitor participants and identify early signs of metastasis. 

Cynvenio Announces Availability of Concordia, a New Cell-free DNA Purification Upgrade for its LiquidBiopsy Whole Blood Enrichment Platform

February 10, 2016 – Cynvenio announces the availability of the Concordia™ cell-free DNA (cfDNA) purification sample preparation upgrade for its multi-template analysis LiquidBiopsy® platform. When coupled with Thermo Fisher Scientific’s Ion Torrent™ next-generation sequencing (NGS) systems, Cynvenio’s workflow provides a comprehensive molecular characterization of tumor cell DNA for cancer research samples from a standard blood draw.